Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Reports Strong Q4 Revenue Growth Amid Swelling Losses

NEW YORK, Aug. 21 - Myriad Genetics today reported strong fourth-quarter revenue growth, a surge in R&D spending, and a ballooning net loss.


For the period ended June 30 the company posted $14.1 million in total receipts compared with $10.8 million for the same time one year ago.


R&D spending echoed every other cost center and grew in the current fourth quarter to $10.7 million from $7.2 million in the same period 2001, Myriad said.


As a result, fourth-quarter net loss swelled to $6.8 million, or $.29 per share, from $2.2 million, or $.09 per share, year over year, according to the company.


Myriad said it had about $124.2 million in cash and investments as of June 30.


Click here for more information.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.